Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses… Read more
Altamira Therapeutics Ltd (CYTO) - Net Assets
Latest net assets as of March 2024: $6.46 Million USD
Based on the latest financial reports, Altamira Therapeutics Ltd (CYTO) has net assets worth $6.46 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.69 Million) and total liabilities ($1.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.46 Million |
| % of Total Assets | 83.94% |
| Annual Growth Rate | 24.35% |
| 5-Year Change | 7.0% |
| 10-Year Change | -87.88% |
| Growth Volatility | 194.63 |
Altamira Therapeutics Ltd - Net Assets Trend (2011–2023)
This chart illustrates how Altamira Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Altamira Therapeutics Ltd (2011–2023)
The table below shows the annual net assets of Altamira Therapeutics Ltd from 2011 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $6.46 Million | +177.68% |
| 2022-12-31 | $-8.31 Million | -165.45% |
| 2021-12-31 | $12.70 Million | -24.24% |
| 2020-12-31 | $16.77 Million | +177.83% |
| 2019-12-31 | $6.04 Million | +65.39% |
| 2018-12-31 | $3.65 Million | +268.79% |
| 2017-12-31 | $-2.16 Million | -115.29% |
| 2016-12-31 | $14.14 Million | -68.39% |
| 2015-12-31 | $44.74 Million | -16.03% |
| 2014-12-31 | $53.28 Million | +489.83% |
| 2013-12-31 | $9.03 Million | +3801.80% |
| 2012-12-31 | $-244.03K | -151.64% |
| 2011-12-31 | $472.58K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Altamira Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 440614500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.65K | 0.04% |
| Other Comprehensive Income | $177.58K | 2.75% |
| Other Components | $24.32 Million | 376.61% |
| Total Equity | $6.46 Million | 100.00% |
Altamira Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Altamira Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COLRUYT
BE:EFC1
|
$318.19K |
|
PILGRIMS PRIDE
BE:6PP
|
$318.26K |
|
Klimat X Developments Inc.
V:KLX
|
$318.33K |
|
AVISTA
BE:AV6
|
$318.40K |
|
MUTUIONLINE
BE:MNL
|
$317.95K |
|
Ginegar
TA:GNGR
|
$317.55K |
|
Gruppo Mutuionline SpA
STU:MNL
|
$317.50K |
|
NATURENERGIE
SW:NEAG
|
$317.47K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Altamira Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -8,314,811 to 6,458,717, a change of 14,773,528.
- Net loss of 7,270,038 reduced equity.
- Other comprehensive income decreased equity by 80,461.
- Other factors increased equity by 22,124,027.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.27 Million | -112.56% |
| Other Comprehensive Income | $-80.46K | -1.25% |
| Other Changes | $22.12 Million | +342.55% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Altamira Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-541.10 | $0.12 | x |
| 2013-12-31 | $20030.26 | $0.12 | x |
| 2014-12-31 | $76998.55 | $0.12 | x |
| 2015-12-31 | $55442.38 | $0.12 | x |
| 2016-12-31 | $16483.51 | $0.12 | x |
| 2017-12-31 | $-1976.43 | $0.12 | x |
| 2018-12-31 | $918.15 | $0.12 | x |
| 2019-12-31 | $415.00 | $0.12 | x |
| 2020-12-31 | $1115.39 | $0.12 | x |
| 2021-12-31 | $383.64 | $0.12 | x |
| 2022-12-31 | $-182.60 | $0.12 | x |
| 2023-12-31 | $13.15 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Altamira Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -112.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-112.56%) is below the historical average (-100.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.58 Million |
| 2013 | -166.10% | 0.00% | 0.00x | 2.91x | $-15.91 Million |
| 2014 | -34.13% | -604.35% | 0.05x | 1.12x | $-23.51 Million |
| 2015 | -66.39% | 0.00% | 0.00x | 1.18x | $-34.18 Million |
| 2016 | -216.80% | 0.00% | -0.01x | 2.52x | $-32.08 Million |
| 2017 | 0.00% | -7580.58% | 0.02x | 0.00x | $-24.19 Million |
| 2018 | -315.00% | -908.09% | 0.13x | 2.71x | $-11.86 Million |
| 2019 | -109.87% | 0.00% | -0.01x | 1.53x | $-7.24 Million |
| 2020 | -48.90% | -4699.91% | 0.01x | 1.24x | $-9.88 Million |
| 2021 | -136.88% | -27222.33% | 0.00x | 1.48x | $-18.66 Million |
| 2022 | 0.00% | -8680.31% | 0.05x | 0.00x | $-25.70 Million |
| 2023 | -112.56% | 0.00% | 0.00x | 1.19x | $-7.92 Million |
Industry Comparison
This section compares Altamira Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Altamira Therapeutics Ltd (CYTO) | $6.46 Million | 0.00% | 0.19x | $317.98K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |